结核性硬化综合体早期发作治疗策略的发展:一项审查和治疗算法
1Division of Child Neurology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Epilepsy & behavior : E&B
|November 2, 2024
概括
像维加巴特林,埃弗罗利木斯和大麻这样的新疗法可以改善患有结核性硬化综合体 (TSC) 的幼儿的发作控制. 一个拟议的算法指导早期诊断和治疗,以获得更好的神经发育结果.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 儿科 儿科 儿科
背景情况:
- 结核性硬化综合体 (TSC) 是一种遗传性疾病,在婴儿中的患病率很高 (80-90%).
- 在TSC中早期的发作与不良的神经发育结果相关,需要及时干预.
研究的目的:
- 审查在幼儿中TSC相关发作的不断发展的治疗方法.
- 为了检查vigabatrin,everolimus和cannabidiol的疗效和安全性.
- 为早期TSC发作提出治疗算法.
主要方法:
- 对vigabatrin,everolimus和cannabidiol的临床试验和现实世界的证据的审查.
- 预先使用维加巴林的分析.
- 逐步治疗算法的开发.
主要成果:
- 维加巴特林,埃弗罗利斯和大麻醇在治疗TSC相关发作方面表现有前途.
- 拟议的算法将新疗法与传统方法相结合.
- 专注于早期诊断和及时,逐步治疗至关重要.
结论:
- 优化TSC的治疗策略需要解决诸如副作用等挑战.
- 改善控制可以使年轻TSC患者的发育结果更好.
- 该评论为临床医生提供了管理早期TSC发作的指导.
相关概念视频
Arteries of the Lower Limbs
178
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
Electroconvulsive Therapy
25
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
25
Seizures: Classification
303
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
303
Antiepileptic Drugs: Glutamate Antagonists
284
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
284
Antiepileptic Drugs: GABAergic Pathway Potentiators
334
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
334
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
255
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
255


